QCG
NTLA icon

Quadrant Capital Group’s Intellia Therapeutics NTLA Stock Holding History

Quadrant Capital Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Sell
1,052
-99
-9% -$1.26K ﹤0.01% 2120
2025
Q4 		$10.3K Hold
1,151
– – ﹤0.01% 2198
2025
Q3 		$19.9K Buy
+1,151
New +$14.2K ﹤0.01% 1956
2025
Q2 		– Sell
-2,520
Closed -$17.9K – 2166
2025
Q1 		$17.9K Buy
2,520
+2,058
+445% +$20.8K ﹤0.01% 2065
2024
Q4 		$5.39K Buy
462
+419
+974% +$6.54K ﹤0.01% 2282
2024
Q3 		$884 Sell
43
-570
-93% -$13.1K ﹤0.01% 2609
2024
Q2 		$13.7K Buy
613
+231
+60% +$5.5K ﹤0.01% 2007
2024
Q1 		$10.5K Sell
382
-94
-20% -$2.61K ﹤0.01% 2085
2023
Q4 		$14.5K Buy
476
+436
+1,090% +$12.5K ﹤0.01% 1933
2023
Q3 		$1.26K Buy
40
+9
+29% +$349 ﹤0.01% 2458
2023
Q2 		$1.26K Sell
31
-166
-84% -$6.73K ﹤0.01% 2479
2023
Q1 		$7.34K Buy
197
+179
+994% +$7.02K ﹤0.01% 2142
2022
Q4 		$628 Sell
18
-148
-89% -$7.04K ﹤0.01% 2596
2022
Q3 		$9K Hold
166
– – ﹤0.01% 1931
2022
Q2 		$9K Buy
166
+130
+361% +$6.6K ﹤0.01% 1728
2022
Q1 		$3K Sell
36
-25
-41% -$2.12K ﹤0.01% 2072
2021
Q4 		$7K Sell
61
-79
-56% -$9.9K ﹤0.01% 1772
2021
Q3 		$19K Buy
140
+80
+133% +$12.1K ﹤0.01% 1265
2021
Q2 		$10K Buy
60
+28
+88% +$2.18K ﹤0.01% 1575
2021
Q1 		$3K Buy
+32
New +$2.15K ﹤0.01% 1967
2020
Q2 		– Sell
-15
Closed – – 2344
2020
Q1 		$0 Buy
+15
New +$202 ﹤0.01% 2216

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quadrant Capital Group's NTLA Position: Q1 2026 in Review

Quadrant Capital Group reduced its Intellia Therapeutics (NTLA) stake by 8.6% in Q1 2026, selling an estimated $1.26K and leaving 1,052 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2120.

Quadrant Capital Group first reported a position in NTLA in Q1 2020 and has held it in 21 quarters since. The position peaked at $19.9K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Quadrant Capital Group held 1,052 shares of Intellia Therapeutics worth $13.5K as of Q1 2026.
  • Quadrant Capital Group sold 99 Intellia Therapeutics shares in Q1 2026, an estimated $1.26K.
  • Intellia Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2120 holding.
  • Quadrant Capital Group first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Quadrant Capital Group's Intellia Therapeutics position peaked at $19.9K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.